BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 17, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/14 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Price target Neutral 2% $21.75
Raymond
Raymond lowered his target to $25 from $31. He noted a survey of 99 U.S. neurologists conducted in mid-August indicated overall market share for multiple sclerosis drug Ampyra dalfampridine was down to 8.1% from 9.5% in May and 13.8% in February. Raymond also noted a court ruling last month increases the likelihood of generic Zanaflex tizanidine. In September, a U.S. district court ruled that claims in an Acorda patent covering tizanidine compositions are invalid and not infringed by an ANDA from Apotex Inc. (see BioCentury, Sept. 12). Ampyra is an oral sustained-release formulation of...

Read the full 814 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >